Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/9/1960 |
| _version_ | 1827655827567149056 |
|---|---|
| author | Syed Faraz Ahmed Muhammad Saqib Sohail Ahmed Abdul Quadeer Matthew R. McKay |
| author_facet | Syed Faraz Ahmed Muhammad Saqib Sohail Ahmed Abdul Quadeer Matthew R. McKay |
| author_sort | Syed Faraz Ahmed |
| collection | DOAJ |
| description | Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and are considered an important outbreak control measure. Viruses observed in the current outbreak carry distinct genetic variations that have the potential to affect vaccine-induced immune recognition. Here, by investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins, we report data that anticipates immune responses induced by VACV-based vaccines, including the currently available MVA-BN and ACAM2000 vaccines, to remain highly cross-reactive against the newly observed monkeypox viruses. |
| first_indexed | 2024-03-09T22:13:03Z |
| format | Article |
| id | doaj.art-33cc545c1ea241618f31ffc91192e4a9 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T22:13:03Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-33cc545c1ea241618f31ffc91192e4a92023-11-23T19:27:07ZengMDPI AGViruses1999-49152022-09-01149196010.3390/v14091960Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox VirusSyed Faraz Ahmed0Muhammad Saqib Sohail1Ahmed Abdul Quadeer2Matthew R. McKay3Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, AustraliaDepartment of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, ChinaDepartment of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, ChinaDepartment of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, AustraliaBeginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and are considered an important outbreak control measure. Viruses observed in the current outbreak carry distinct genetic variations that have the potential to affect vaccine-induced immune recognition. Here, by investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins, we report data that anticipates immune responses induced by VACV-based vaccines, including the currently available MVA-BN and ACAM2000 vaccines, to remain highly cross-reactive against the newly observed monkeypox viruses.https://www.mdpi.com/1999-4915/14/9/1960monkeypoxvaccinia virusvaccinesimmunitygenetic similarityT cells |
| spellingShingle | Syed Faraz Ahmed Muhammad Saqib Sohail Ahmed Abdul Quadeer Matthew R. McKay Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus Viruses monkeypox vaccinia virus vaccines immunity genetic similarity T cells |
| title | Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus |
| title_full | Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus |
| title_fullStr | Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus |
| title_full_unstemmed | Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus |
| title_short | Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus |
| title_sort | vaccinia virus based vaccines are expected to elicit highly cross reactive immunity to the 2022 monkeypox virus |
| topic | monkeypox vaccinia virus vaccines immunity genetic similarity T cells |
| url | https://www.mdpi.com/1999-4915/14/9/1960 |
| work_keys_str_mv | AT syedfarazahmed vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus AT muhammadsaqibsohail vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus AT ahmedabdulquadeer vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus AT matthewrmckay vacciniavirusbasedvaccinesareexpectedtoelicithighlycrossreactiveimmunitytothe2022monkeypoxvirus |